MIR221 (MicroRNA 221)

Additionally, MYCN-induced miR-221 was found to suppress CREB expression. Together, these findings demonstrate MYCN-dependent effects of TrkC signalling and highlight the therapeutic potential of targeting the PKA pathway to induce differentiation in high-risk MYCN-amplified neuroblastoma.

Moreover, we identified a 13-miR signature, comprising miRs regulated by both APE1 and AUF1, that exhibits strong prognostic value in cervical cancer. These findings suggest a novel potential role of both APE1 and AUF1 as therapeutic targets in cervical cancer.

Emerging strategies offering potential solutions include engineered exosomes and localized implantable systems. Understanding the spatiotemporal dynamics of miRNA-mediated organotropism, facilitated by advanced technologies, will be crucial for the future development of precision therapies to combat TNBC metastasis.

The binding affinity of the modified PNAs to their targets and their ability to inhibit miR-221-3p expression were considerably higher than those of unmodified PNAs in Lung cancer cell lines, leading to effective regulation of downstream gene and protein expression. These findings underscore the potential of γ-modified PNAs as a platform for developing miRNA-targeted therapeutics.

Using this probe to analyze miR-21 and miR-221 in lung cancer cells, we found that both miRNAs were significantly upregulated in lung cancer cell line A549 compared to human embryonic kidney cell line HEK-293T, and only miR-21 was upregulated in breast cancer cell line MCF-7. By optimizing experimental conditions, the optimal reaction conditions were determined as 1 nM S1/S2, 10 nM C1/C2, and 200 μM dNTPs for co-centration, 60 min for initial amplification, 6 h for T4 DNA polymerase, and 120 min for phi29 DNA polymerase.

From a therapeutic point of view, miR-199a-3p replacement synergized with palbociclib and overcame sorafenib resistance. This review highlights the importance of the TG221 transgenic mouse as a powerful model for studying miRNA-driven hepatocarcinogenesis and enables preclinical evaluation of RNA-based chemopreventive and therapeutic approaches. Metformin, miRNA inhibition, miRNA replacement and miRNA-guided viral therapies emerge as promising approaches for advancing precision prevention and treatment strategies in HCC.

Our study identifies miR-221-3p as the most promising miRNA for the diagnosis of lung cancer in Kashmiri population. These findings contribute to the growing knowledge of lung cancer biomarkers and may facilitate early detection and improved clinical management in the Kashmiri population.

The practical significance of this work lies in the possibility of considering the identified genomic and epigenomic features when choosing surgical intervention and adjuvant therapy, thereby increasing the chances for long-term remission. Additionally, it emphasizes the standardization of analytical methods and the development of a unified system for evaluating the combined genetic alterations, which could enhance the quality of prognostic stratification and more effectively tailor treatment strategies.

In vivo experiment of subcutaneous tumor formation in nude mice verified that miRNA-221/222 promoted tumor growth by targeting PHACTR4. In conclusion, miRNA-221/222 played the role of proto-oncogene in the occurrence and development of pituitary tumors by targeting PHACTR4, which provided a new target for the diagnosis and molecular treatment of pituitary adenomas.

Furthermore, to enhance reliability in complex biological environments, an artificial neural network algorithm was implemented, achieving a correlation coefficient (R2) of 0.985. The DFMN sensor holds broad application prospects in interdisciplinary fields such as human-machine interaction, smart healthcare, and artificial intelligence, providing an innovative solution for real-time sensitive detection of wearable flexible sensors.

The dual-response activation design effectively reduces false positive signals, thereby enhancing the detection and imaging accuracy. This method provides a novel design concept for utilizing split-DNA activation of the CRISPR/Cas system for nucleic acid detection and cell imaging.